Aimmune Therapeutics, focused on therapies to treat food, gastrointestinal (GI), and metabolic-related allergies, has released positive results from its three controlled phase 3 of Palforzia allergen powder. The results, published in the Journal of Allergy and Clinical Immunology (JACI), showed a consistent and manageable safety profile with continued treatment. The US FDA had approved PALFORZIA as an oral immunotherapy for the mitigation of allergic reactions, including anaphylaxis, that may occur with accidental exposure to peanuts for patients aged 4 to 17 years in early 2020.